Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide.


Journal

Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777

Informations de publication

Date de publication:
01 2020
Historique:
received: 15 09 2019
revised: 24 10 2019
accepted: 11 11 2019
pubmed: 30 11 2019
medline: 23 4 2021
entrez: 30 11 2019
Statut: ppublish

Résumé

Endothelial dysfunction is an earlier contributor to the development of atherosclerosis in chronic kidney disease (CKD), in which the role of epigenetic triggers cannot be ruled out. Endothelial protective strategies, such as defibrotide (DF), may be useful in this scenario. We evaluated changes induced by CKD on endothelial cell proteome and explored the effect of DF and the mechanisms involved. Human umbilical cord vein endothelial cells were exposed to sera from healthy donors (n = 20) and patients with end-stage renal disease on haemodialysis (n = 20). Differential protein expression was investigated by using a proteomic approach, Western blot and immunofluorescence. HDAC1 and HDAC2 overexpression was detected. Increased HDAC1 expression occurred at both cytoplasm and nucleus. These effects were dose-dependently inhibited by DF. Both the HDACs inhibitor trichostatin A and DF prevented the up-regulation of the endothelial dysfunction markers induced by the uraemic milieu: intercellular adhesion molecule-1, surface Toll-like receptor-4, von Willebrand Factor and reactive oxygen species. Moreover, DF down-regulated HDACs expression through the PI3/AKT signalling pathway. HDACs appear as key modulators of the CKD-induced endothelial dysfunction as specific blockade by trichostatin A or by DF prevents endothelial dysfunction responses to the CKD insult. Moreover, DF exerts its endothelial protective effect by inhibiting HDAC up-regulation likely through PI3K/AKT.

Identifiants

pubmed: 31782253
doi: 10.1111/jcmm.14865
pmc: PMC6991634
doi:

Substances chimiques

Polydeoxyribonucleotides 0
Reactive Oxygen Species 0
Toll-Like Receptor 4 0
von Willebrand Factor 0
Intercellular Adhesion Molecule-1 126547-89-5
defibrotide 438HCF2X0M
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Histone Deacetylases EC 3.5.1.98

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1713-1723

Informations de copyright

© 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Références

Blood Adv. 2018 Jun 26;2(12):1495-1509
pubmed: 29945939
J Am Soc Nephrol. 2006 Jul;17(7):2034-47
pubmed: 16738019
Mol Cell Proteomics. 2019 Mar 15;18(Suppl 1):S77-S90
pubmed: 30518674
J Leukoc Biol. 2010 Jun;87(6):1103-14
pubmed: 20200406
Mol Med. 2011 May-Jun;17(5-6):378-90
pubmed: 21274504
Mol Cell Proteomics. 2019 Mar 15;18(Suppl 1):S46-S58
pubmed: 30287546
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):1967-72
pubmed: 22308472
Mol Cell Proteomics. 2013 Feb;12(2):330-42
pubmed: 23161514
Clin Exp Nephrol. 2009 Apr;13(2):145-151
pubmed: 19101780
Lancet. 2017 Oct 21;390(10105):1888-1917
pubmed: 28434650
Eur J Clin Invest. 2015 Feb;45(2):160-9
pubmed: 25496217
Haematologica. 2002 Oct;87(10):1053-61
pubmed: 12368160
J Neurosci. 2017 Aug 2;37(31):7547-7559
pubmed: 28663197
Vascul Pharmacol. 2013 Jul-Aug;59(1-2):1-10
pubmed: 23680861
Cancer Biol Ther. 2007 May;6(5):686-90
pubmed: 17495522
N Engl J Med. 2009 Apr 2;360(14):1395-407
pubmed: 19332456
Immunology. 2007 Dec;122(4):596-606
pubmed: 17635610
Contrib Nephrol. 2008;161:55-62
pubmed: 18451658
Trends Immunol. 2011 Jul;32(7):335-43
pubmed: 21570914
Transl Stroke Res. 2018 Oct;9(5):471-483
pubmed: 29218547
Clin Chim Acta. 2010 Oct 9;411(19-20):1412-20
pubmed: 20598675
Blood. 2010 Mar 25;115(12):2483-90
pubmed: 20053759
Mol Oncol. 2012 Dec;6(6):637-56
pubmed: 23141799
PLoS One. 2012;7(8):e43374
pubmed: 22937042
Hypertension. 2010 Sep;56(3):437-44
pubmed: 20679181
Biol Blood Marrow Transplant. 2011 Apr;17(4):497-506
pubmed: 21126597
J Cell Mol Med. 2020 Jan;24(2):1713-1723
pubmed: 31782253
Nephrol Dial Transplant. 2003 Jun;18(6):1079-85
pubmed: 12748338
Exp Cell Res. 2001 Jan 15;262(2):75-83
pubmed: 11139331
J Clin Invest. 1973 Nov;52(11):2745-56
pubmed: 4355998
Hypertension. 2009 May;53(5):860-6
pubmed: 19273737
Circ Res. 2008 Apr 25;102(8):873-87
pubmed: 18436802
J Clin Invest. 1997 Jun 1;99(11):2561-4
pubmed: 9169483
Thromb Haemost. 2001 Oct;86(4):1099-105
pubmed: 11686330
Leukemia. 2003 Aug;17(8):1636-42
pubmed: 12886253
Cardiol Res Pract. 2011;2011:267257
pubmed: 21637718
Am J Kidney Dis. 2008 Apr;51(4):603-12
pubmed: 18371536
Am J Pathol. 2011 May;178(5):2205-14
pubmed: 21514434
Nat Rev Mol Cell Biol. 2006 Jun;7(6):437-47
pubmed: 16723979
Int J Cardiol. 2016 Aug 1;216:68-77
pubmed: 27140339
Annu Rev Pharmacol Toxicol. 2012;52:303-19
pubmed: 21942627
Am J Physiol Heart Circ Physiol. 2014 Sep 1;307(5):H803-9
pubmed: 25015965
Cell Physiol Biochem. 2018;51(3):1287-1300
pubmed: 30481789
Clin J Am Soc Nephrol. 2008 Mar;3(2):505-21
pubmed: 18184879
Cardiovasc Res. 2011 Jun 1;90(3):413-20
pubmed: 21233251
PLoS One. 2017 Oct 18;12(10):e0186620
pubmed: 29045501
Cell Cycle. 2010 Sep 15;9(18):3680-4
pubmed: 20930523
Blood. 2011 Jan 27;117(4):1205-17
pubmed: 20956800
J Biochem Biophys Methods. 1994 Apr;28(3):239-42
pubmed: 8064118
Circulation. 2010 Jan 5;121(1):132-42
pubmed: 20026773
Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39
pubmed: 27477773
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2652-9
pubmed: 17008592
Blood. 2016 Mar 31;127(13):1719-27
pubmed: 26755708

Auteurs

Marta Palomo (M)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.
Josep Carreras Leukaemia Research Institute, Hospital Clinic/University of Barcelona Campus, Barcelona, Spain.
Barcelona Endothelium Team (BET), Barcelona, Spain.

Manel Vera (M)

Nephrology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.

Susana Martin (S)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.

Sergi Torramadé-Moix (S)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.

Julia Martinez-Sanchez (J)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.
Josep Carreras Leukaemia Research Institute, Hospital Clinic/University of Barcelona Campus, Barcelona, Spain.
Barcelona Endothelium Team (BET), Barcelona, Spain.

Ana Belen Moreno (A)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.

Enric Carreras (E)

Josep Carreras Leukaemia Research Institute, Hospital Clinic/University of Barcelona Campus, Barcelona, Spain.
Barcelona Endothelium Team (BET), Barcelona, Spain.

Ginés Escolar (G)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.

Aleix Cases (A)

Nephrology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.

Maribel Díaz-Ricart (M)

Hematopathology, Centre Diagnòstic Biomèdic (CDB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Barcelona, Spain.
Barcelona Endothelium Team (BET), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH